Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis.
The objective is to report a patient with concomitant ankylosing spondylitis (AS) and Behçet's disease (BD) successfully treated with adalimumab. A 44-year-old male diagnosed as AS applied to our outpatient clinic with complaints of morning stiffness, pain and limitation of motion at spine, concurrence of oral and genital ulcerated lesions. He was on sulfasalazine together with different NSAIDs for the past 1 year. According to the criteria of International Study Group, he was diagnosed as BD. The patient was considered as refractory to current treatment and adalimumab treatment was started. During follow-up, not only AS was in remission, but also no new oral and genital ulcerations appeared. There were no complications related to the use of anti-TNFalpha therapy. In our case it was observed that anti-TNFalpha therapy, specifically adalimumab, was effective for symptoms of both AS and BD.
Yildiz
Necmettin
N
Medicine Faculty, Pamukkale University, Denizli, Turkey.
Alkan
Hakan
H
Ardic
Fusun
F
Topuz
Oya
O
D000068879:Adalimumab; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab
Rev Rhum Engl Ed. 1995 Apr;62(4):295-9
7606426
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25
19022808
Ann Rheum Dis. 2004 Jun;63(6):744-5
15140785
Eye (Lond). 2007 Jun;21(6):824-5
16601736
J Clin Rheumatol. 2006 Dec;12(6):282-6
17149058
Ann Rheum Dis. 2001 Jun;60(6):637
11350856
Curr Opin Rheumatol. 1996 Jul;8(4):275-87
8864578
Ann Rheum Dis. 1981 Dec;40(6):558-9
7332375
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii51-3
12379622
Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S99-102
17949561
Curr Opin Rheumatol. 1994 Jan;6(1):39-43
8031678
Rheumatology (Oxford). 2007 May;46(5):736-41
17403712
Ann Rheum Dis. 2007 Apr;66(4):565-6
17124248
Eur J Ophthalmol. 1995 Jul-Sep;5(3):192-4
8845689
Rheumatol Int. 2000;19(5):195-8
10984138
J Rheumatol. 1997 Jan;24(1):128-32
9002023
Clin Rheumatol. 1996 Nov;15(6):619-20
8973876
J Rheumatol. 2005 Jan;32(1):98-105
15630733
Arthritis Rheum. 1998 Apr;41(4):694-700
9550479
Ann Rheum Dis. 1988 Sep;47(9):780-3
3178318
Br J Rheumatol. 1992 May;31(5):299-308
1581771
Arthritis Rheum. 1995 Apr;38(4):499-505
7718003
Arthritis Rheum. 1984 Apr;27(4):361-8
6231933